Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Current Opinion in Pharmacology|October 11, 2020
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?Dahham Alsoud, Séverine Vermeire, Bram Verstockt
Current Research in Pharmacology and Drug Discovery|February 11, 2022
Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promisesDahham Alsoud, Séverine Vermeire, Bram Verstockt
The Lancet. Gastroenterology & Hepatology|May 21, 2021
Breaking the therapeutic ceiling in drug development in ulcerative colitisDahham Alsoud, Bram Verstockt, Claudio Fiocchi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2024
Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel DiseaseDahham Alsoud, João Sabino, Marc Ferrante, et al.
Inflammatory Bowel Diseases|November 9, 2021
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBDAnnick Moens, Bram Verstockt, Dahham Alsoud, et al.
The American Journal of Gastroenterology|September 27, 2023
Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative ColitisDahham Alsoud, Jessica Ho, João Sabino, et al.
European Journal of Gastroenterology & Hepatology|September 5, 2022
Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral centerAnnick Moens, Dahham Alsoud, Bram Verstockt, et al.
Therapeutic Advances in Gastroenterology|September 1, 2023
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's diseaseNathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, et al.
Journal of Crohn'S & Colitis|February 12, 2022
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for AllPadhmanand Sudhakar, Dahham Alsoud, Judith Wellens, et al.
British Journal of Clinical Pharmacology|February 19, 2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseasesWannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
Pageof 2